From liver cirrhosis to HCC

Area of Science:

• Hepatology
• Oncology
• Gastroenterology

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of mortality in patients with Child-A cirrhosis.
• Surveillance for early HCC detection is essential in Child-A and selected Child-B cirrhotic patients eligible for liver transplantation.
• Early diagnosis via surveillance can lead to stage migration and improved survival in specific patient groups.

Purpose of the Study:

• To review the current recommendations and strategies for hepatocellular carcinoma surveillance in patients with liver cirrhosis.
• To highlight the role of imaging versus serological markers in early HCC detection.
• To emphasize the importance of a multidisciplinary approach in managing HCC and cirrhosis.

Main Methods:

• Review of current guidelines and literature on hepatocellular carcinoma surveillance in cirrhotic patients.
• Discussion of the diagnostic algorithm for nodule detection based on size.
• Evaluation of the Barcelona Clinic Liver Cancer (BCLC) staging system's role in treatment selection.

Main Results:

• Ultrasound is the sole recommended surveillance tool for hepatocellular carcinoma in cirrhotic patients, with 6-month intervals.
• Serum markers, including alpha-fetoprotein (AFP), are not currently recommended for surveillance.
• A size-based algorithm guides the diagnostic workup upon detecting a new nodule.

Conclusions:

• Regular ultrasound surveillance is critical for the early detection of hepatocellular carcinoma in cirrhotic patients.
• The BCLC staging system aids in treatment decisions, but individualized multidisciplinary evaluation is necessary.
• Effective management requires addressing both hepatocellular carcinoma and underlying liver cirrhosis concurrently.